Phil Vickers
President/CEO
Solu Therapeutics
–/10Traction
Solu Therapeutics develops a cytotoxicity-targeting chimera platform that links bifunctional small molecules to proprietary antibodies, enabling the selective elimination of disease-driving cells in oncology and autoimmune conditions. This approach addresses the challenge of targeting previously inaccessible cell surface proteins, enhancing therapeutic efficacy while minimizing safety risks.
- Biotechnology
Updated 5 months ago
Funding
Raised to date
$70.3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Many cell surface proteins are difficult to target with traditional antibody therapies due to their structure or inaccessibility. This limitation hinders the development of effective treatments for diseases where these proteins play a critical role.
Solution
Solu Therapeutics is developing a CyTAC (Cytotoxicity Targeting Chimera) platform that creates bifunctional small molecules to target previously inaccessible cell surface proteins. The platform links these small molecules to proprietary antibodies, enabling the selective elimination of disease-driving cells in oncology and autoimmune conditions. Solu's linker technology allows the bifunctional small molecules to adopt the pharmacokinetic properties and functions of the antibodies. This approach enhances therapeutic efficacy while minimizing safety risks by using low doses of small molecules. The company is also developing TicTAC (Therapeutic Index Control Targeting Chimera) molecules, which drive the tight association of potent and selective small molecule agonists or antagonists with an Fc-modified antibody, leading to the small molecule assuming the pharmacokinetic characteristics of the antibody.
Target Audience
The primary target audience includes patients with cancer, autoimmune diseases, and inflammatory conditions, as well as pharmaceutical companies seeking innovative drug development platforms.
Features
- CyTACs: Link cell surface targets on pathogenic cells to antibodies that induce cell killing.
- TicTACs: Drive association of small molecule agonists/antagonists with Fc-modified antibodies for optimized therapeutic profiles.
- Targets high-value cell surface proteins, including GPCRs and ion channels, that are not addressable by traditional antibodies.
- Rapid drug development: Covalent attachment of linkers to clinical-quality small molecules accelerates the path from concept to development candidate.
- Enhanced specificity and efficacy: Low small molecule doses minimize safety risks, while deep binding pockets enhance antibody efficacy.
- STX-0712: A CCR2-CyTAC in Phase 1 clinical trials for chronic myelomonocytic leukemia (CMML) and other advanced hematologic malignancies, designed to deplete pathogenic monocytes.
- STX-0812: A CCR2-CyTAC in preclinical development for inflammatory diseases, also designed to deplete pathogenic monocytes.
- STX-0640: A novel targeting CyTAC in preclinical development for inflammatory diseases, designed to deplete mast cells.
- Na ion channel TicTACs: Preclinical programs for potent and long-acting antagonism of sodium ion channels for pain management.